Plasma Cell Myeloma Refractory Clinical Trial
Official title:
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
The primary purpose of this study is to assess the efficacy (overall response rate) of subcutaneous (SC) via on body delivery system (SC-OBDS) isatuximab in combination with weekly carfilzomib and dexamethasone (Kd) in adult participants with RRMM having received 1 to 3 prior lines of therapy.
The duration of the study for a participant will include a period for screening of up to 28 days. A cycle duration is 28 days. After study treatment discontinuation, participants will return to the study site 30 days after the last dose of study treatment for the end-of-treatment (EOT) visit or before further anti-myeloma therapy initiation, whichever comes first. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04643002 -
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
|
Phase 1/Phase 2 |